Loading...
Market
What will be the market valuation of companies involved in developing the new prime editing gene therapy for CFTR F508del mutation by the end of 2024?
2
Resolution / Starting Odds
Company A exceeds $10 billion • 25%
Company B exceeds $10 billion • 25%
Both companies exceed $10 billion • 25%
Neither company exceeds $10 billion • 25%
Financial reports and stock market data
Story
New Gene Editing Advances Show Promise for Treating CFTR F508del Mutation in Cystic Fibrosis
Jul 10, 2024, 12:02 PM
Recent advancements in gene editing have shown promising results in treating cystic fibrosis (CF). Scientists have developed a prime editing approach that efficiently corrects the most common CF mutation, CFTR F508del, in primary airway cells from CF patients. This method could pave the way for a one-time treatment as effective as existing daily therapies. Additionally, new lipid nanoparticle designs have enabled targeted in vivo lung editing in mice, potentially leading to new treatment options for CF. Researchers are optimistic about the potential of these developments to offer a permanent solution for CF patients.
View original story
Similar markets
Pfizer • 25%
Moderna • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
No clinical trials • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Positive • 33%
Neutral • 33%
Negative • 34%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
Yes • 33%
No • 34%
Top 3 but not best-selling • 33%
FDA (USA) • 25%
EMA (Europe) • 25%
MHRA (UK) • 25%
Other • 25%
USA • 25%
UK • 25%
Germany • 25%
Other • 25%